0001564590-21-055347 | 10-Q | XBRL Viewer | Acadia Pharmaceuticals INC

Label	Element	Value
Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases	acad_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	$ 1,000
Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases	acad_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	1,000
Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases	acad_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	1,066,000
Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases	acad_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	11,714,000
Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases	acad_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	10,060,000
Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases	acad_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	58,899,000
Collaborative Arrangements Upfront Payment	acad_CollaborativeArrangementsUpfrontPayment	5,000,000.0
Collaborative Arrangements Upfront Payment	acad_CollaborativeArrangementsUpfrontPayment	10,000,000.0
Collaborative Arrangements Upfront Payment	acad_CollaborativeArrangementsUpfrontPayment	10,000,000.0
Collaborative Arrangements Upfront Payment	acad_CollaborativeArrangementsUpfrontPayment	$ 10,000,000.0
Number Of Renewal Option Terms	acad_NumberOfRenewalOptionTerms	2
Equity Securities Fv Ni Unrealized Losses	acad_EquitySecuritiesFvNiUnrealizedLosses	$ 40,000
Compensation Expense Related To Mergers To Former Holders	acad_CompensationExpenseRelatedToMergersToFormerHolders	887,000,000.0
Accrued Clinical Development Services Current	acad_AccruedClinicalDevelopmentServicesCurrent	20,930,000
Accrued Clinical Development Services Current	acad_AccruedClinicalDevelopmentServicesCurrent	28,380,000
Increase Decrease In Operating Lease Assets	acad_IncreaseDecreaseInOperatingLeaseAssets	(4,794,000)
Increase Decrease In Operating Lease Assets	acad_IncreaseDecreaseInOperatingLeaseAssets	$ (2,863,000)
Number Of Motions	acad_NumberOfMotions	5
Capitalization Of Right Of Use Asset	acad_CapitalizationOfRightOfUseAsset	$ 40,300,000
Capitalization Of Right Of Use Asset	acad_CapitalizationOfRightOfUseAsset	19,200,000
Increase Decrease In Operating Lease Liabilities	acad_IncreaseDecreaseInOperatingLeaseLiabilities	(4,044,000)
Increase Decrease In Operating Lease Liabilities	acad_IncreaseDecreaseInOperatingLeaseLiabilities	(587,000)
Debt Securities And Equity Securities Fv Ni	acad_DebtSecuritiesAndEquitySecuritiesFvNi	445,651,000
Debt Securities And Equity Securities Fv Ni	acad_DebtSecuritiesAndEquitySecuritiesFvNi	305,930,000
Accrued Sales Allowances Current	acad_AccruedSalesAllowancesCurrent	8,050,000
Accrued Sales Allowances Current	acad_AccruedSalesAllowancesCurrent	14,115,000
Collaborative Arrangements Assets Acquisition And Upfront Payment	acad_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment	45,700,000
Regulatory Milestone Payment	acad_RegulatoryMilestonePayment	8,000,000.0
Capitalization Of Lease Liability	acad_CapitalizationOfLeaseLiability	40,300,000
Capitalization Of Lease Liability	acad_CapitalizationOfLeaseLiability	$ 19,200,000
Obligation Expiration Year	acad_ObligationExpirationYear	2021
Debt Securities And Equity Securities Fv Ni Amortized Cost	acad_DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	$ 445,663,000
Debt Securities And Equity Securities Fv Ni Amortized Cost	acad_DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	305,899,000
License Fees And Royalty Expense	acad_LicenseFeesAndRoyaltyExpense	2,994,000
License Fees And Royalty Expense	acad_LicenseFeesAndRoyaltyExpense	2,796,000
License Fees And Royalty Expense	acad_LicenseFeesAndRoyaltyExpense	8,181,000
License Fees And Royalty Expense	acad_LicenseFeesAndRoyaltyExpense	7,546,000
Debt Securities And Equity Securities Fv Ni Unrealized Gains	acad_DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	28,000
Debt Securities And Equity Securities Fv Ni Unrealized Gains	acad_DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	74,000
Accrued Branded Prescription Drug Fees Current	acad_AccruedBrandedPrescriptionDrugFeesCurrent	1,959,000
Accrued Branded Prescription Drug Fees Current	acad_AccruedBrandedPrescriptionDrugFeesCurrent	1,845,000
Debt Securities And Equity Securities Fv Ni Unrealized Losses	acad_DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	40,000
Debt Securities And Equity Securities Fv Ni Unrealized Losses	acad_DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	$ 43,000
Collaborative Arrangements Upfront Payment Description	acad_CollaborativeArrangementsUpfrontPaymentDescription	The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.
Collaborative Arrangements Non Cash Upfront Payment	acad_CollaborativeArrangementsNonCashUpfrontPayment	$ 44,300,000
Collaborative Arrangements Upfront License Fee	acad_CollaborativeArrangementsUpfrontLicenseFee	$ 10,000,000.0
Collaborative Arrangements Upfront Payment Shares Issued	acad_CollaborativeArrangementsUpfrontPaymentSharesIssued	1,200,000
Equity Securities Fv Ni Unrealized Gains	acad_EquitySecuritiesFvNiUnrealizedGains	$ 28,000
Collaborative Arrangements Upfront Consideration And Transaction Payment	acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment	52,800,000
Corporate Office Space Lease Agreement [Member]
Lessee Operating Lease Lease Not Yet Commenced Minimum Lease Payments	acad_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments	50,400,000
Lessee Operating Lease Lease Not Yet Commenced Minimum Lease Payments	acad_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments	25,300,000
Lessee Operating Lease Lease Not Yet Commenced Minimum Lease Payments	acad_LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments	$ 51,400,000

Leases - Summary of Maturities of Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2021 USD ($)
Operating Lease Liabilities [Abstract]
Thereafter	$ 44,275

Print Document View Excel Document
Notes Details Leases - Summary of Maturities of Lease Liabilities (Detail) Uncategorized Uncategorized Items - acad-10q_20210930_htm.xml All Reports